Publication Topic

Grover A, Sankaranarayanan S, Mathur V, Suri P, Qiu H, Andrews-Zwilling Y, Mease K, Taylor LK, Cahir-McFarland E, Keswani S, Yednock T. 2023. Pharmacokinetic and target engagement measures of ANX007, an anti-C1q antibody fragment, following intravitreal administration in nonhuman primates. Invest Opthalmol Visual Sci 64(2)3; 10.1167/iovs.64.2.3.

Ramírez-Valle F, Adams M, Beebe L, Chen J, Chuaqui C, Connarn JN, Corin AF, Dingley KH, et al. 2019. A novel MK2 inhibitor for the treatment of ankylosing spondylitis and other inflammatory diseases. Abstract 1536, Annual Meeting of the American College of Rheumatology Conference, Atlanta, GA, November 2019.

Thompson CM, Kirman CR, Hays SM, Suh M, Harvey SE, Proctor DM, Rager JE, Haws LC, Harris MA. 2018. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. J Appl Toxicol 38:351–365. doi: 10.1002/jat.3545.

Harper BH, Wang L, Zhu C, Kar NF, Li B, Moyes CR, … Dingley K, et al. 2017. Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder. Bioorg Med Chem Lett 27(4):1094–1098; doi: 10.1016/j.bmcl.2016.12.033. PMID: 28089699.

Zhu C, Wang L, Zhu Y, Guo ZZ, Liu P, Hu Z, … Dingley KH, et al. 2017. Discovery of phenyl acetamides as potent and selective GPR119 agonists. Bioorg Med Chem Lett 27(5):1124–1128; doi: 10.1016/j.bmcl.2017.01.091. PMID: 28185720.

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. 2013. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX.

Kirman CR, Hays SM, Aylward LL, Suh M, Proctor D. 2012. Physiologically-based pharmacokinetic model for mice, rats and humans orally-exposed to chromium. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, March 6-10, 2011, Washington, D.C.

Thompson CM, Capdevila JH, Strobel HW. 2000. Recombinant P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exper Ther 294(3):1120–1130.